Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
N/A N=284 Bronchial Thermoplasty in Severe Persistent Asthma
Severe Asthma
Primary: Subjects Experiencing Severe Exacerbations (Rates) — 132; 118; 118; 106 Participants
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
Phase 2 N=36 Targeted Therapy of Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans
Primary: Number of Subjects Who Failed Treatment — 2 Participants
Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
N/A N=40 Lung Collapse With Bronchial Blocker
Video-assisted Thoracoscopic Surgery · Lung Isolation Device · One-lung Ventilation
Primary: Time to Obtain Complete Lung Collapse — 47.8; 32.5 minutes
N/A N=21 Airway Inflammation in Congenital Diaphragmatic Hernia Patients
Congenital Diaphragmatic Hernia
Primary: Number of Participants With Elevated Sputum Eosinophils — 0 participants
Phase 4 N=26 Treatment of Tracheostomy Granulomas
Granuloma · Tracheostomy
Primary: Success and Failure Rates for Each Treatment Method — 6; 3; 5; 3 Participants
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
N/A N=10 PEEP Mask for Tracheobronchomalacia-Induced Cough
Tracheobronchomalacia
Primary: Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS) — -50.67 units on a scale — p=0.108
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
N/A N=10 CrYobiopsy With Radial UltraSound Guidance
Pulmonary Disease
Primary: Time to Achieve Hemostasis After Obtaining Cryobiopsy — 146.55; 132.25 seconds — p=0.7878
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 4 N=12 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2